In muscle-invasive bladder cancer, the presence of IL-22+ cells in the tumor was associated with poor prognosis and increased expression of exhaustion markers such as PD-1, CTLA-4, TIM3, and LAG-3 in CD8+ T cells, but also with a better response to Nivolumab in in vitro assays with freshly resected tumor tissue (93). This evidence concerns the gene IL22 and neoplasm.